Elevated LOX expression drives excessive cross-linking of collagen and is associated with poor prognosis in a range of cancers [60], whilst LOX inhibition delays cancer progression in pre-clinical models of primary [33] and metastatic cancer [34], although to date, has failed to demonstrate efficacy in humans [35]. This evidence concerns the gene LOX and metastatic malignant neoplasm.